פרה-קיור

🔬 Advancing Ex-Vivo Models with an Integrative Approach 🔬 Incorporating functional testing with viability assessments in 3D biological samples allows for a deeper and more precise understanding of drug responses. This advanced approach enhances the predictive accuracy of preclinical models, leading to a more efficient drug development process. By identifying successful drug candidates early and optimizing therapeutic strategies, researchers can reduce time and costs, thus offering safer and more effective therapies. Ultimately, this integration improves patient outcomes by ensuring that treatments are tailored to individual needs, enhancing both their safety and efficacy. #3DBiologicalSamples #FunctionalTesting #PreCure

Join Our Team: Research Assistant at Pre-Cure Pre-Cure is a young and dynamic start-up company based in Jerusalem, dedicated to developing a cutting-edge platform for personalized therapy in oncology using a unique bioengineering technology. At Pre-Cure, we foster a collaborative and close-knit environment where talented individuals like yourself can thrive. We are passionate about our mission and invite you to be a part of our journey as we revolutionize cancer treatment. Job Description: As a Research Assistant, you will play a crucial role in the success of our research projects. Your responsibilities will include: - Laboratory management and operation. - Working with patient-derived mammalian cell samples and ex vivo models - Collaborating with clinicians to perform clinical studies. Requirements: - Hold an MSc in life sciences. - Possess 1-3 years of industry or academic experience conducting hands-on lab research. - Demonstrate proficiency in mammalian cell cultures and cell biology techniques. - Exhibit the ability to independently design and troubleshoot experiments. - Have excellent English language skills. Advantages: - Background in tissue engineering and 3D cell culture techniques. - Experience in designing and fabricating microfluidic devices. - Proficiency in experimental techniques such as cell-based assays and live-cell imaging. How to Apply: Please submit your resume in the designated section below or alternatively, you may send an email with your resume attached to info@pre-cure.bio. Pre-Cure is an Equal Employment Opportunity Employer that is committed to diversity, equity, and inclusion. We take unbiased action to offer employment and advancement opportunities to all applicants, without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or ability status. Our methods for hiring include ensuring that all available opportunities are fairly promoted — via online globally available channels — in a manner accessible to all potential applicants

Wishing you a year filled with happiness and groundbreaking discoveries! From Pre-Cure team 🍎🍯🌟🍷🥳🌰🌿🍏

Join Our Team: Research Assistant at Pre-Cure Pre-Cure is a young and dynamic start-up company based in Jerusalem, dedicated to developing a cutting-edge platform for personalized therapy in oncology using a unique bioengineering technology. At Pre-Cure, we foster a collaborative and close-knit environment where talented individuals like yourself can thrive. We are passionate about our mission and invite you to be a part of our journey as we revolutionize cancer treatment. Job Description: As a Research Assistant, you will play a crucial role in the success of our research projects. Your responsibilities will include: - Laboratory management and operation. - Working with patient-derived mammalian cell samples and ex vivo models - Collaborating with clinicians to perform clinical studies. Requirements: - Hold an MSc in life sciences. - Possess 1-3 years of industry or academic experience conducting hands-on lab research. - Demonstrate proficiency in mammalian cell cultures and cell biology techniques. - Exhibit the ability to independently design and troubleshoot experiments. - Have excellent English language skills. Advantages: - Background in tissue engineering and 3D cell culture techniques. - Experience in designing and fabricating microfluidic devices. - Proficiency in experimental techniques such as cell-based assays and live-cell imaging. How to Apply: Please submit your resume in the designated section below or alternatively, you may send an email with your resume attached to info@pre-cure.bio. Pre-Cure is an Equal Employment Opportunity Employer that is committed to diversity, equity, and inclusion. We take unbiased action to offer employment and advancement opportunities to all applicants, without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or ability status. Our methods for hiring include ensuring that all available opportunities are fairly promoted — via online globally available channels — in a manner accessible to all potential applicants

It is estimated that more than 115 million animals worldwide are used in laboratory experiments every year. Why We Still Use Animals for Drug Development—and How Emerging Technologies Will Change That? Join Us for Another Episode of Pre-Cure Edge! For decades, animal models have played a critical role in drug development, providing insights that have advanced our understanding of diseases and therapeutic interventions. However, as we strive for more ethical and effective research practices, it’s clear that we must transition toward innovative alternatives. Emerging technologies, such as Pre-Cure tumor-on-a-chip and 3D cell culture systems, are paving the way for this change. As the scientific community embraces the Three R's—Replacement, Reduction, and Refinement—we are seeing a shift toward advanced in vitro models that have the potential to revolutionize how we conduct research. 🔄 Replacement encourages the use of alternative methods to avoid the need for animal testing. With advanced technologies like organ-on-a-chip and tumor-on-a-chip models, we can simulate human biological responses more accurately. These systems empower researchers to study disease processes and drug effects in a dynamic and relevant environment. 📏 Reduction emphasizes minimizing the number of animals used in research. By implementing cutting-edge in vitro techniques, researchers gather comprehensive data while using fewer animal subjects and resources. This is not just a win for ethical practices—it contributes to building a more sustainable research landscape. 🧪 Refinement focuses on improving experimental techniques to enhance animal welfare when animals are used. Although the emphasis is shifting toward in vitro models, refinement also includes enhancing how we analyze and interpret data from these systems. For example, 3D cell cultures and tumor-on-a-chip models provide more precise testing conditions, leading to better insights and outcomes. The integration of these innovative technologies aligns with the Three R's and paves the way for more effective and responsible scientific discovery. By leveraging in vitro models, we can ensure that our research is both ethically sound and scientifically rigorous. As we move forward, let’s champion the adoption of the Three R's within our research communities and support a future where science and ethics go hand in hand! 🌱✨ #ThreeRs #EthicalResearch #InVitroModels #TumorOnAChip #3DCellCulture #BiomedicalResearch #Innovation

 Exciting Update Our CSO, Prof. Ofra Benny, delivered a compelling lecture on the latest advancements in drug delivery for oncology at the "Bringing Academia and Industry Together: Drug Delivery Devices - Devices and Technologies for Drug Delivery" event organized by the Israel Innovation Authority רשות החדשנות. Her presentation highlighted the rational design of biodegradable devices and showcased the critical role of advanced drug delivery systems in revolutionizing targeted and personalized medicine. Special thanks to Yael Hay-Knobel for organizing this impactful event that bridges academia and industry. #Drug_Delivery_Devices #Academia_and_Industry #

The Importance of Flexibility in Drug Screening Models In the world of cancer research, flexibility is essential. Rigid and fixed models can often stifle innovation, forcing researchers to adapt their studies or abandon valuable approaches. We are excited to highlight one of our key capabilities that enhances flexibility in cancer research! Using our advanced 3D-printed microfluidic devices, we successfully cultivate cancer spheroids and monolayer cells over extended periods. But that’s not all, our unique models allow for complete access to samples at any time point without destruction, enabling a seamless workflow. This means you can extract a sample during an experiment under flow conditions, conduct vital analyses, and then return it to the system to continue your research. Below, you can see Human Choriocarcinoma spheroids formed within 24 hours using our 3D-printed molds with micro-wells. Additionally, prostate cancer cells stained with Calcein AM (green) demonstrate high viability after culture under flow conditions in our 3D-printed chip. Want to learn more? Follow Pre-Cure and stay updated with our latest innovations!

Let’s dive into the exciting world of patient-derived tumor spheroids (PDTS) and see how they're revolutionizing cancer research, immunotherapy, and chemotherapy. Imagine having mini versions of real human tumors in the lab, that’s what PDTS are all about! These 3D models give researchers a closer look at how cancer cells behave and respond to treatments. They’re like a secret weapon for developing personalized therapies that target cancer where it hurts. In immunotherapy, PDTS helps scientists figure out how to boost the immune system to fight cancer more effectively. And when it comes to chemotherapy, these spheroids let researchers test different drugs to find the best match for each patient. PDTS maintains the complexity and diversity of a patient’s original tumor, preserving important interactions and structures. This allows researchers to study how cancer cells grow and react in conditions that mimic the human body. By using PDTS, scientists can customize treatments on an individual level, offering valuable insights for personalized medicine and improving predictions of treatment success. Not only do PDTS provide a window into cancer behavior, but they also offer a platform for testing new drugs and therapies before they move into clinical trials on patients. This leads to faster and more efficient development of personalized treatments. Pre-Cure's technology is based on patient-derived tumor spheroids that we believe will revolutionize personalized medicine. We’re excited to be at the forefront of this transformation and look forward to sharing more updates as we progress. Curious to know more about our innovations? Feel free to reach out! 🎉🔬 Photo Credit: Steinberg E, Orehov N, Tischenko K, Schwob O, Zamir G, Hubert A, Manevitch Z, Benny O. Rapid Clearing for High Resolution 3D Imaging of Ex Vivo Pancreatic Cancer Spheroids. Int J Mol Sci. 2020 Oct 18;21(20):7703. doi: 10.3390/ijms21207703. PMID: 33081011; PMCID: PMC7589457. #3DHumanCellModels #Spheroids #CancerResearch #3DCellCulture #PersonalizedMedicine #CancerTherapies

I’m excited to share that I will be speaking at the upcoming End-of-Year-Event at The Hebrew University of Jerusalem's Rothberg International School, focusing on the collaboration between industry and academia. I’ll share Pre-Cure's story and our journey from lab bench to market, along with insights on how to successfully commercialize academic research. I’ll also talk about the great benefits of turning academic innovations into real-world solutions, especially at the Hebrew University and through Yissum, The Hebrew University Tech Transfer Company, which played a key role in our journey. Looking forward to seeing you there! #EndOfYearEvent #IndustryAndAcademia #Techtransfer #PreCure Maor Tirry

Here is a sad fact: Kids From Poorer Families Less Likely to Survive Cancer. A new study published three months ago in the Journal of the American College of Surgeons, shows that a childhood childhood cancer patient’s risk of dying within five years of their diagnosis increases by 4% for every one-point increase in their neighborhood’s Area Deprivation Index (ADI). This impressive article, which spans nearly 25 years and involves 3,863 pediatric cancer patients, really caught my attention and made me realize that personalized medicine has the potential not only to improve survival rates but also reduce inequality in access to medical services and enhance outcomes in low socioeconomic groups. Here are two reasons why: Reducing the Burden: By tailoring treatments to individual patients, technologies like Pre-Cure’s "tumor-on-a-chip" platform aim to optimize therapeutic outcomes and prevent ineffective therapies. Effective personalized medicine not only improves patient outcomes but also has the potential to substantially reduce healthcare costs. This reduction in costs can enable insurers to offer broader coverage to all policyholders or lower the overall cost of insurance and enhance the quality of care. For context, consider that American insurers have the potential to spend nearly half a billion dollars annually on ineffective treatments for ovarian cancer alone. This is a significant sum that could be spread and reallocated towards providing more medical services per formulary (a list of prescription medications that are covered by a particular health insurance plan). One Shot to Get It Right: Patients without gold-platinum insurance levels (which are usually high-coverage policies) that cover advanced treatments often face a critical one-chance scenario since they have a limited budget for one treatment. Personalized treatments are crucial in these situations, especially since new treatments may lack comprehensive statistical data to guide physicians. Even when data exists, it often shows a lack of response in a certain percentage of cases, leaving much in the hands of fate. By advancing personalized medicine solutions and preventing ineffective treatments, we can make a significant impact on breaking these heartbreaking equations. Pre-Cure Edge is a weekly series of articles exploring the impact of personalized medicine on cancer treatment. Our focus includes cutting-edge "tumor on a chip" technology and advanced 3D cell culture models, highlighting their influence on cancer care. Visit our website to learn more: https://www.pre-cure.bio/ Read the full article - https://lnkd.in/dcNr8xkK